About Capping protein, Arp2/3 and myosin-I linker protein 3
Capping protein, Arp2/3 and myosin-I linker protein 3 (CARMIL3) is a protein
from Homo sapiens identified by UniProt accession
Q8ND23, 1372 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | Capping protein, Arp2/3 and myosin-I linker protein 3 |
|---|
| UniProt accession | Q8ND23 |
|---|
| Gene | CARMIL3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1372 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (16)
Diseases linked to this target (Open Targets).
- triglyceride measurement · score 0.10
- stroke · score 0.02
- Ataxia-telangiectasia · score 0.02
- Stroke · score 0.02
- Leishmaniasis · score 0.01
- neoplasm · score 0.01
- brucellosis · score 0.01
- COVID-19 · score 0.01
- ulcerative colitis · score 0.01
- visceral Leishmaniasis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8ND23-F1 | alphafold | PREDICTED | 64.40 | — |
Amino-acid sequence (1372 residues)
MAKPSVELTR ELQDSIRRCL SQGAVLQQHH VKLETKPKKF EDRVLALTSW RLHLFLLKVP AKVESSFNVL EIRAFNTLSQ NQILVETERG MVSMRLPSAE SVDQVTRHVS SALSKVCPGP GCLIRRGNAD TPEGPRDTSP NSETSTSTTH SVCGGFSETY AALCDYNGLH CREEVQWDVD TIYHAEDNRE FNLLDFSHLE SRDLALMVAA LAYNQWFTKL YCKDLRLGSE VLEQVLHTLS KSGSLEELVL DNAGLKTDFV QKLAGVFGEN GSCVLHALTL SHNPIEDKGF LSLSQQLLCF PSGLTKLCLA KTAISPRGLQ ALGQTFGANP AFASSLRYLD LSKNPGLLAT DEANALYSFL AQPNALVHLD LSGTDCVIDL LLGALLHGCC SHLTYLNLAR NSCSHRKGRE APPAFKQFFS SAYTLSHVNL SATKLPLEAL RALLQGLSLN SHLSDLHLDL SSCELRSAGA QALQEQLGAV TCVGSLDLSD NGFDSDLLTL VPALGKNKSL KHLFLGKNFN VKAKTLEEIL HKLVQLIQEE DCSLQSLSVA DSRLKLRTSI LINALGSNTC LAKVDLSGNG MEDIGAKMLS KALQINSSLR TILWDRNNTS ALGFLDIARA LESNHTLRFM SFPVSDISQA YRSAPERTED VWQKIQWCLV RNNHSQTCPQ EQAFRLQQGL VTSSAEQMLQ RLCGRVQEEV RALRLCPLEP VQDELLYARD LIKDAKNSRA LFPSLYELGH VLANDGPVRQ RLESVASEVS KAVDKELQVI LESMVSLTQE LCPVAMRVAE GHNKMLSNVA ERVTVPRNFI RGALLEQAGQ DIQNKLDEVK LSVVTYLTSS IVDEILQELY HSHKSLARHL TQLRTLSDPP GCPGQGQDLS SRGRGRNHDH EETTDDELGT NIDTMAIKKQ KRCRKIRPVS AFISGSPQDM ESQLGNLGIP PGWFSGLGGS QPTASGSWEG LSELPTHGYK LRHQTQGRPR PPRTTPPGPG RPSMPAPGTR QENGMATRLD EGLEDFFSRR VLEESSSYPR TLRTVRPGLS EAPLPPLQKK RRRGLFHFRR PRSFKGDRGP GSPTTGLLLP PPPPPPPTQE SPPSPDPPSL GNNSSPCWSP EEESSLLPGF GGGRGPSFRR KMGTEGSEPG EGGPAPGTAQ QPRVHGVALP GLERAKGWSF DGKREGPGPD QEGSTQAWQK RRSSDDAGPG SWKPPPPPQS TKPSFSAMRR AEATWHIAEE SAPNHSCQSP SPASQDGEEE KEGTLFPERT LPARNAKLQD PALAPWPPKP VAVPRGRQPP QEPGVREEAE AGDAAPGVNK PRLRLSSQQD QEEPEVQGPP DPGRRTAPLK PKRTRRAQSC DKLEPDRRRP PDPTGTSEPG TD
Explore Capping protein, Arp2/3 and myosin-I linker protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets